Research Report on China's Heparin Export 2023-2032
Heparin is a natural and highly sulfated glycosaminoglycan anticoagulant. Heparin API is the raw material for antithrombotic and anticoagulant drugs such as low molecular weight heparin preparations, which are widely used in cardiovascular, cerebrovascular, joint replacement, hemodialysis and other surgeries and treatments. With the accelerating trend of global population aging, the prevalence of cardiovascular diseases and the improvement of residents' health awareness, the market size of heparin is also gradually expanding.
China is one of the major heparin exporters in the world, exporting a large amount of heparin every year. According to CRI analysis, in 2021, China exported 125.05 tons of heparin, down 17.72% year-on-year, with an export value of US$1,597 million, up 20.86% year-on-year. From January to November 2022, China exported 132.00 tons of heparin, up 18.05% year-on-year, with an export value of US$1,441 million, up 1.90% year-on-year.
In 2021, China exported heparin to more than sixty countries and regions worldwide. CRI analysis shows that Hong Kong, China, Italy, India, Japan and the Russian Federation are the major export destinations of heparin from China by export volume. Among them, Hong Kong, China is the largest destination for China's heparin exports. In 2021, China exported 40.59 tons of heparin to Hong Kong, China, accounting for 32.46% of the total heparin exports in that year, and the export value was US$455 million, accounting for 28.49% of the total export value.
China is a major global producer and exporter of heparin APIs, and CRI expects the Chinese heparin export market to remain stable in the future.
Topics covered:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook